Leqembi Iqlik® for initiation treatment launched in the US

RegulatoryapprovedLeqembi IqlikPositive

AI Analysis

Summary

Eisai announced that lecanemab-irmb subcutaneous injection (Leqembi Iqlik®) received FDA approval on July 13, 2026 and is now available in the US for initiation therapy in Alzheimer's disease. BioArctic AB is partnered with Eisai on this development.

Outcome Details

FDA approved lecanemab-irmb subcutaneous injection on July 13, 2026; now available in US

Importance:8/10

Sentiment:

0.90

FDA approvalLeqembisubcutaneous formulationAlzheimer's diseaseBioArcticEisaiproduct launch

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Biotech on August 24, 2026 12:39 PM

Read Original